Vertex Expands FDA Approval For CASGEVY In Children With Sickle Cell Disease And Beta Thalassemia

Vertex (VRTX) said the U.S. FDA approved expanded CASGEVY use for patients ages 2+ with sickle cell disease who experience vaso-occlusive crises or have transfusion-dependent beta thalassemia. The label expansion meaningfully broadens the eligible population, supporting upside to commercial opportunity versus prior approvals.

Analysis

Vertex (VRTX) said the U.S. FDA approved expanded CASGEVY use for patients ages 2+ with sickle cell disease who experience vaso-occlusive crises or have transfusion-dependent beta thalassemia. The label expansion meaningfully broadens the eligible population, supporting upside to commercial opportunity versus prior approvals.